Related Experiment Video
Updated: Mar 6, 2026
10:31
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
791
Antidiabetic Drugs and the Kidney
Vasilis Tsimihodimos1, Nikolaos Karanatsis1, Eleftheria Tzavela1
1Department of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece.
Current Pharmaceutical Design
|March 9, 2017
Summary
Diabetic nephropathy is a common diabetes complication. New antidiabetic drugs, like sodium glucose cotransporter 2 inhibitors, show promise in protecting kidneys and may slow diabetic nephropathy progression.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Diabetic nephropathy is a major complication of diabetes mellitus.
- Kidney function significantly impacts the effectiveness of glucose-lowering medications.
- Interactions between antidiabetic drugs and renal function are complex.
Purpose of the Study:
- To review the relationship between antidiabetic drugs and kidney function.
- To summarize evidence on drugs inhibiting renal glucose reabsorption.
- To explore renoprotective effects of glucose-lowering agents.
Main Methods:
- Comprehensive literature review of PubMed articles up to 2016.
- Focus on studies examining antidiabetic drugs and kidney interactions.
- Analysis of pharmacokinetic and pharmacodynamic changes in renal impairment.
Main Results:
- Drugs inhibiting proximal glucose reabsorption are available.
- Some antidiabetic drugs may offer kidney protection independent of glucose control.
- Dose adjustments for antidiabetic drugs in kidney disease are discussed.
Conclusions:
- Sodium glucose cotransporter 2 inhibitors are promising for type 2 diabetes, especially with cardiovascular disease.
- These drugs, pioglitazone, and incretin mimetics may reduce diabetic nephropathy incidence and progression.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
762
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
762
01:06Oral Hypoglycemic Agents: Glinides
780
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
780
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
704
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
704
01:23Dipeptidyl Peptidase 4 Inhibitors
814
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
814
01:16Antihypertensive Drugs: Action of Diuretics
2.6K
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
2.6K
01:22Heart Failure Drugs: Diuretics
1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K